Having only recently entered the SBIR arena, Accure Medical personnel are employing received Phase I funding to work on development of a treatment for Onychomycosis using Targeted, Controlled High-Frequency Energy. In the broader context, the frm is usefully understood as structured around development of various forms of medication relavent to addressing those patients suffering from the range of conditions that are CNS - diseases of the Central nervous system.
